3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
6
Lymphoma, T-Cell, Peripheral
6
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma
6
Leukemia, Myeloid, Acute
6
Lymphoma, T-Cell, Cutaneous
5
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
5
Recurrence
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, T-Cell
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Lung Neoplasms
4
Hodgkin Disease
4
Hematologic Neoplasms
4
Waldenstrom Macroglobulinemia
3
Urinary Bladder Neoplasms
3
Sarcoma
3
Neoplasms
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoblastic Lymphadenopathy
3
Fallopian Tube Neoplasms
3
Burkitt Lymphoma
3
Thyroid Neoplasms
2
Interventions
pembrolizumab
93
Gemcitabine
55
Nivolumab
49
Cisplatin
38
atezolizumab
31
Carboplatin
30
enfortumab vedotin
25
avelumab
25
Docetaxel
23
Magnetic Resonance Spectroscopy
18
Ipilimumab
17
Paclitaxel
16
Mitomycin
15
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Injections
7
Cyclophosphamide
7
tislelizumab
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Transitional Cell
×
belinostat
×
Clear all
NCT05154994
2026-05-07
RESOLVE
University of Utah
Phase 1
Active not recruiting
9 enrolled